tetano
Editor, Senior Moderator
J Clin Med
. 2023 Mar 3;12(5):2019.
doi: 10.3390/jcm12052019.
High Plasma tPAPAI-1C Levels May Be Related to a Poor Prognosis in Patients with Severe or Critical COVID-19: A Single-Center Retrospective Study
Kunihiro Shirai[SUP] 1 [/SUP], Michiko Ishikawa[SUP] 1 [/SUP], Tomoyuki Kobayashi[SUP] 1 [/SUP], Kiyoko Sato[SUP] 1 [/SUP], Hiromoto Murakami[SUP] 1 [/SUP], Keisuke Kohama[SUP] 1 [/SUP], Naomi Manbo[SUP] 1 [/SUP], Kana Hasegawa[SUP] 2 [/SUP], Junichi Hirata[SUP] 1 [/SUP]
Affiliations
Abstract
Severe novel coronavirus disease 2019 (COVID-19) patients have a high incidence of thrombotic complications and mortality. The pathophysiology of coagulopathy involves fibrinolytic system impairment and vascular endothelial damage. This study examined coagulation and fibrinolytic markers as outcome predictors. In an observational study of 164 COVID-19 patients admitted to our emergency intensive care unit, hematological parameters on days 1, 3, 5, and 7 were retrospectively compared between survivors and nonsurvivors. Nonsurvivors had a higher APACHE II score, SOFA score, and age than survivors. Nonsurvivors also had a significantly lower platelet count and significantly higher plasmin/α2plasmin inhibitor complex (PIC), tissue plasminogen activator/plasminogen activator inhibitor-1 complex (tPAPAI-1C), D-dimer, and fibrin/fibrinogen degradation product (FDP) levels than survivors throughout the measurement period. The 7-day maximum or minimum values of the tPAPAI-1C, FDP, and D-dimer levels were significantly higher in nonsurvivors. A multivariate logistic regression analysis showed that the maximum tPAPAI-1C (OR = 1.034; 95% CI,1.014-1.061; p = 0.0041) was an independent factor affecting mortality, with an area under the curve (AUC) of 0.713 (optimum cut-off of 51 ng/mL; sensitivity, 69.2%; and specificity, 68.4%). COVID-19 patients with poor outcomes exhibit exacerbated coagulopathy with fibrinolysis inhibition and endothelial damage. Consequently, plasma tPAPAI-1C might be a useful predictor of the prognosis in patients with severe or critical COVID-19.
Keywords: COVID-19; coagulopathy; endothelial damage; fibrinolysis; tPAPAI-1C.
. 2023 Mar 3;12(5):2019.
doi: 10.3390/jcm12052019.
High Plasma tPAPAI-1C Levels May Be Related to a Poor Prognosis in Patients with Severe or Critical COVID-19: A Single-Center Retrospective Study
Kunihiro Shirai[SUP] 1 [/SUP], Michiko Ishikawa[SUP] 1 [/SUP], Tomoyuki Kobayashi[SUP] 1 [/SUP], Kiyoko Sato[SUP] 1 [/SUP], Hiromoto Murakami[SUP] 1 [/SUP], Keisuke Kohama[SUP] 1 [/SUP], Naomi Manbo[SUP] 1 [/SUP], Kana Hasegawa[SUP] 2 [/SUP], Junichi Hirata[SUP] 1 [/SUP]
Affiliations
- PMID: 36902805
- DOI: 10.3390/jcm12052019
Abstract
Severe novel coronavirus disease 2019 (COVID-19) patients have a high incidence of thrombotic complications and mortality. The pathophysiology of coagulopathy involves fibrinolytic system impairment and vascular endothelial damage. This study examined coagulation and fibrinolytic markers as outcome predictors. In an observational study of 164 COVID-19 patients admitted to our emergency intensive care unit, hematological parameters on days 1, 3, 5, and 7 were retrospectively compared between survivors and nonsurvivors. Nonsurvivors had a higher APACHE II score, SOFA score, and age than survivors. Nonsurvivors also had a significantly lower platelet count and significantly higher plasmin/α2plasmin inhibitor complex (PIC), tissue plasminogen activator/plasminogen activator inhibitor-1 complex (tPAPAI-1C), D-dimer, and fibrin/fibrinogen degradation product (FDP) levels than survivors throughout the measurement period. The 7-day maximum or minimum values of the tPAPAI-1C, FDP, and D-dimer levels were significantly higher in nonsurvivors. A multivariate logistic regression analysis showed that the maximum tPAPAI-1C (OR = 1.034; 95% CI,1.014-1.061; p = 0.0041) was an independent factor affecting mortality, with an area under the curve (AUC) of 0.713 (optimum cut-off of 51 ng/mL; sensitivity, 69.2%; and specificity, 68.4%). COVID-19 patients with poor outcomes exhibit exacerbated coagulopathy with fibrinolysis inhibition and endothelial damage. Consequently, plasma tPAPAI-1C might be a useful predictor of the prognosis in patients with severe or critical COVID-19.
Keywords: COVID-19; coagulopathy; endothelial damage; fibrinolysis; tPAPAI-1C.